Skip to Content
by Leigh MacMillan | Posted on Wednesday, Apr. 30, 2014 — 11:00 AM
The chemotherapy drug melphalan is a standard treatment for multiple myeloma – particularly in high doses with autologous stem cell transplantation (ASCT). Dose-limiting toxicities of melphalan include myelosuppression and gastrointestinal injury, but the occurrence and severity of these side effects vary between individuals.
Stephen Brandt, M.D., and colleagues investigated whether genetic variation in the transporters that ferry melphalan into cells contributes to inter-individual differences in gastrointestinal complications. They analyzed genetic variation in two transporter genes (SLC7A5 and SLC7A8) in 135 patients with multiple myeloma who were all treated with high-dose melphalan and ASCT, and compared genetic variation to the need for total parenteral nutrition (intravenous feeding suggesting gastrointestinal injury).
The investigators found an association between a single change in SLC7A5 and the need for total parenteral nutrition. The results, published in Biology of Blood and Marrow Transplantation, suggest that variability in transport of melphalan into cells impacts mucosal injury after high-dose treatment and could help individualize melphalan dose.
This research was supported by CTSA award TR000445 from the National Center for Advancing Translational Sciences of the National Institutes of Health.
Send suggestions for articles to highlight in Aliquots and any other feedback about the column to firstname.lastname@example.org
Leigh MacMillan, (615) 322-4747
Health and Medicine, Reporter, Research Aliquots, cancer biology, cell and developmental biology, chemotherapy, CTSA, Department of Medicine, Department of Veterans Affairs, genetic variant, myeloma, NCATS, NIH, personalized medicine, Reporter April 25 2014, side effects, Stephen Brandt, Vanderbilt Ingram Cancer Center
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: